CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Stock Information for Nxu Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nxu Inc.

CNS Pharmaceuticals Announces Reverse Stock Split
CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287
CNS Pharmaceuticals Reports Full Year 2024 Financial Results
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.